Zanzalintinib for aggressive prostate cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug, zanzalintinib, in men with a fast-growing type of prostate cancer that has spread and stopped responding to standard hormone therapies. It aims to see if the drug can help shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced prostate cancer that has spread to other parts of the body.
- You must have tried at least one newer hormone therapy (like enzalutamide or abiraterone) and it stopped working.
- Your cancer must show certain aggressive features, like spread to organs, many bone spots, or genetic changes in specific tumor suppressor genes.
- You must be in generally good health, able to perform daily activities, and have adequate organ function as shown by blood tests.
- You cannot have had certain prior treatments within a few weeks before starting the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called zanzalintinib for people with advanced liver cancer (HCC) that can't be treated with surgery. You may join if your cancer has gotten worse after at least one prior treatment, or you couldn't tolerate that treatment.
This trial tests a new targeted therapy pill (XL092, also called zanzalintinib) for people with certain advanced sarcomas that have not responded to other treatments. The goal is to see if the drug shrinks tumors or slows their growth.
This study tests a new oral medication called zanzalitinib, which may help slow the growth of advanced prostate cancer that has continued to spread despite hormone therapy and possibly chemotherapy. The goal is to see if the drug is safe and effective for men with this type of cancer.
This trial tests a new oral drug, zanzalintinib, for men with advanced prostate cancer that has stopped responding to hormone therapy and who have already been treated with Pluvicto. The goal is to see if this drug can slow the cancer's growth.
This trial tests a new drug called zanzalintinib for people with advanced bladder cancer that has grown after at least one prior treatment. The drug may help shrink tumors or slow their growth.
This trial tests a new drug called zanzalintinib for people with advanced or metastatic bone sarcomas that have not responded to standard treatments. It aims to see if the drug can help shrink or slow the growth of these tumors.
Hear when a new Aggressive Variant Prostate Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.